Physician profile
Mohamed Samour
NPI 1164807574
$1,136.68
in general payments reported to CMS, 2019-2025
10 companies · $128 in 2025
The $128 reported for 2025 was more than what a typical Hematology (Pathology) provider received nationally (typical 2025 total: $118).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $97.64 · 2021: $122 · 2022: $391 · 2023: $64.77 · 2024: $332 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $283 · Food and Beverage: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $282.99 |
| Food and Beverage | $242.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $216.75 | 2023-2025 | Reblozyl |
| Seagen INC. | $202.03 | 2022 | |
| Jazz Pharmaceuticals INC. | $167.93 | 2020-2021 | |
| Lilly USA, LLC | $166.66 | 2024 | |
| Incyte Corporation | $125.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $85.00 | 2024 | Soliris |
| Adaptive Biotechnologies Corporation | $64.30 | 2022 | |
| Abbvie INC. | $51.68 | 2020 | |
| Blueprint Medicines Corporation | $31.33 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $26.00 | 2025 | Breyanzi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamed Samour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.